Compare American International Group Inc (AIG) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American International Group Inc vs Crispr Therapeutics AG — how do they compare? American International Group Inc trades at $77.4 (market cap $40.42B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.23B). The key difference: American International Group Inc is far larger — about 7.7× Crispr Therapeutics AG's market cap, and American International Group Inc pays a 2.59% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AIG | CRSP | |
|---|---|---|
Market Cap | $40.42B | $5.23B |
Sector | Financials | Health |
52-Week High | $86.59 | $76.78 |
52-Week Low | $71.89 | $44.34 |
Enterprise Value | $48.06B | $3.65B |
Dividend Yield | 2.59% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American International Group Inc
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
